- Home
- WNS vs SUPN Comparison
WNS vs SUPN Comparison
Compare WNS & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WNS
- SUPN
- Stock Information
- Founded
- WNS 1996
- SUPN 2005
- Country
- WNS India
- SUPN United States
- Employees
- WNS N/A
- SUPN N/A
- Industry
- WNS Business Services
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- WNS Consumer Discretionary
- SUPN Health Care
- Exchange
- WNS Nasdaq
- SUPN Nasdaq
- Market Cap
- WNS 2.3B
- SUPN 1.9B
- IPO Year
- WNS N/A
- SUPN 2012
- Fundamental
- Price
- WNS $47.27
- SUPN $36.43
- Analyst Decision
- WNS Buy
- SUPN Hold
- Analyst Count
- WNS 7
- SUPN 1
- Target Price
- WNS $60.43
- SUPN $36.00
- AVG Volume (30 Days)
- WNS 473.4K
- SUPN 348.4K
- Earning Date
- WNS 01-16-2025
- SUPN 02-25-2025
- Dividend Yield
- WNS N/A
- SUPN N/A
- EPS Growth
- WNS N/A
- SUPN 130.79
- EPS
- WNS 2.50
- SUPN 1.07
- Revenue
- WNS $1,308,696,000.00
- SUPN $651,972,000.00
- Revenue This Year
- WNS N/A
- SUPN $7.82
- Revenue Next Year
- WNS $7.88
- SUPN N/A
- P/E Ratio
- WNS $18.97
- SUPN $34.05
- Revenue Growth
- WNS 2.07
- SUPN 6.79
- 52 Week Low
- WNS $39.85
- SUPN $25.53
- 52 Week High
- WNS $72.57
- SUPN $39.37
- Technical
- Relative Strength Index (RSI)
- WNS 43.15
- SUPN 52.26
- Support Level
- WNS $45.80
- SUPN $35.73
- Resistance Level
- WNS $47.91
- SUPN $37.34
- Average True Range (ATR)
- WNS 1.57
- SUPN 1.20
- MACD
- WNS 0.07
- SUPN -0.01
- Stochastic Oscillator
- WNS 53.46
- SUPN 69.02
About WNS WNS (Holdings) Limited Sponsored ADR (Jersey)
WNS (Holdings) Ltd is a Global provider of business process management (BPM) services, offering comprehensive data, voice, analytical, and business transformation services with a blended onshore, nearshore and offshore delivery model. The company's segment includes Banking/Financial Services, and Insurance; Travel, Shipping/Logistics, and Utilities; Manufacturing/Retail/Consumer, Hi-tech/Professional Services, and Procurement; Healthcare/Life Sciences. Geographically the company generates the majority of its revenue from North America (primarily the US), followed by the UK. The company also has a presence in Australia, Europe (excluding the UK), and South Africa.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.